Moderna’s stock doubles on promising cancer-vaccine results
First publishedAug 19, 12:15 UTC
Last updatedAug 19, 13:49 UTC · 15m ago
1 outlet
MarketWatch
1 outlets over time — hover a bar for its window & outletslast updated
Answer
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
Reported by 1 outlet — MarketWatch. See all sources ↓
Read the full report at MarketWatch ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
In brief
- What's the story?
- The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 15m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Moderna’s stock doubles on promising cancer-vaccine results
Sources1TypeCoverage
Sources (1)
Avg source rating 7.0/10Processing cluster
A1A2A3B1B2B3